Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.26B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  XLO
Xilio Therapeutics
XLO
55 / 100
Penny Stock
$1.05arrow_drop_down4.54%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$1.08
Prev. Close$1.10
EPS-2.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap40603420.00
PE Ratio-
LOWHIGH
Day Range1.01
1.15
52 Week Range0.49
3.40
Ratios
P/B Ratio1.10
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %13.40%
EBITDA Margin %-
ROE %-107.25%
EPS-2.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

55vs 56. Market Avg.

All Score 55 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

XLOMARKET
Value5240
Quality3140
Ownership3417
Growth6347
Dividends-38
check_circle

Xilio Therapeutics's Price discount from 1 year high of 66.67% is great compared to market average of 18.4%. This indicates XLO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$745.69
24H (%)arrow_drop_up1.96%
24H ($)$14.35
MARKET CAP$695.32B
PRICE$486.17
24H (%)arrow_drop_down1.02%
24H ($)-$5.05
MARKET CAP$452.88B
PRICE$149.56
24H (%)arrow_drop_up0.29%
24H ($)$0.44
MARKET CAP$359.34B
PRICE$126.88
24H (%)arrow_drop_down0.04%
24H ($)-$0.06
MARKET CAP$321.54B

About Xilio Therapeutics (XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
Headquarters
Waltham
Employees
84
Exchange
NASDAQ
add Xilio Therapeutics to watchlist

Keep an eye on Xilio Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Xilio Therapeutics (XLO)?

For Xilio Therapeutics (XLO), the 52-week high is $3.4, which is 223.81% from the current price. The 52-week low is $0.49, the current price is 114.29% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is Xilio Therapeutics's (XLO) price per share?

The current price per share for Xilio Therapeutics (XLO) is $1.05. The stock has seen a price change of -$0.05 recently, indicating a -4.55% change. This reflects the stock's recent market performance and investor sentiment.

help
Is Xilio Therapeutics (XLO) a growth stock?

Xilio Therapeutics (XLO) has shown an average price growth of -43.26% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xilio Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Xilio Therapeutics (XLO) stock price performance year to date (YTD)?

As of the latest data, Xilio Therapeutics (XLO) has a year-to-date price change of 83.28%. Over the past month, the stock has experienced a price change of 50%. Over the last three months, the change has been 64.58%. Over the past six months, the figure is -46.97%.

help
Is Xilio Therapeutics (XLO) a profitable company?

Xilio Therapeutics (XLO) has a net income of -$76.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$79.13M. Furthermore, the EBITDA is -$77.23M.

help
What is the market capitalization of Xilio Therapeutics (XLO)?

Xilio Therapeutics (XLO) has a market capitalization of $40.6M. The average daily trading volume is 353.39K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.